Susquehanna International Group
ADCT icon

Susquehanna International Group’s ADC Therapeutics ADCT Stock Holding History

Susquehanna International Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286K Buy
76,268
+56,090
+278% +$221K ﹤0.01% 10965
2025
Q4 		$71.2K Buy
+20,178
New +$81.9K ﹤0.01% 11620
2025
Q3 		– Sell
-115,232
Closed -$363K – 12247
2025
Q2 		$309K Buy
115,232
+11,452
+11% +$24.1K ﹤0.01% 10275
2025
Q1 		$146K Buy
103,780
+52,582
+103% +$89.3K ﹤0.01% 11253
2024
Q4 		$102K Buy
+51,198
New +$134K ﹤0.01% 11330
2024
Q3 		– Sell
-54,126
Closed -$171K – 11860
2024
Q2 		$171K Buy
+54,126
New +$215K ﹤0.01% 10555
2024
Q1 		– Sell
-20,689
Closed -$76.3K – 12056
2023
Q4 		$34.3K Buy
+20,689
New +$19.1K ﹤0.01% 11844
2023
Q3 		– Sell
-18,788
Closed -$40.4K – 11922
2023
Q2 		$40.4K Sell
18,788
-7,240
-28% -$16.3K ﹤0.01% 11415
2023
Q1 		$50.8K Buy
26,028
+12,065
+86% +$44.5K ﹤0.01% 11698
2022
Q4 		$53.6K Sell
13,963
-3,959
-22% -$15.8K ﹤0.01% 11353
2022
Q3 		$86K Buy
+17,922
New +$130K ﹤0.01% 11814
2022
Q1 		– Sell
-25,866
Closed -$411K – 12882
2021
Q4 		$522K Buy
+25,866
New +$624K ﹤0.01% 9075
2021
Q3 		– Sell
-32,124
Closed -$823K – 12654
2021
Q2 		$782K Sell
32,124
-67,164
-68% -$1.56M ﹤0.01% 8437
2021
Q1 		$2.42M Buy
99,288
+90,694
+1,055% +$2.63M ﹤0.01% 5443
2020
Q4 		$275K Buy
+8,594
New +$282K ﹤0.01% 9433

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's ADCT Position: Q1 2026 in Review

Susquehanna International Group increased its ADC Therapeutics (ADCT) stake by 278% in Q1 2026, buying an estimated $221K and bringing the position to 76,268 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #10965.

Susquehanna International Group first reported a position in ADCT in Q4 2020 and has held it in 15 quarters since. The position peaked at $2.42M in Q1 2021. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Susquehanna International Group held 76,268 shares of ADC Therapeutics worth $286K as of Q1 2026.
  • Susquehanna International Group bought 56,090 ADC Therapeutics shares in Q1 2026, an estimated $221K.
  • ADC Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10965 holding.
  • Susquehanna International Group first reported a position in ADC Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Susquehanna International Group's ADC Therapeutics position peaked at $2.42M in Q1 2021.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.